Cooperative Agreement NU51IP000928

Award Date 9/30/21
Completion Date 9/29/26
Dollars Obligated $1.4M
Funding Federal Agency
Center for Global Health
Awarding Federal Agency
Office of Financial Resources
Federal Grant Program
93.283
Assistance Type
Cooperative Agreement
Place of Performance
San Francisco, CA, USA
Similar Awards
This Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Global AIDS program (CFDA 93.067) provides $4,838,896 to the Cameroon Baptist Convention Health Board (CBCHB) to develop, implement, and sustain high-quality comprehensive facility and community-based HIV 95-95-95 cascade activities for children, adolescents, and adults in Cameroon. The award supports a range of technical assistance, service delivery, and capacity-building activities aimed at...
The Centers for Disease Control and Prevention (CDC) awarded a $15,221,142 Cooperative Agreement under the Global AIDS program (CFDA 93.067) to the Association Camerounaise Pour LE Marketing Social (ACMS) in Cameroon. The five-year award, beginning September 30, 2024, aims to develop, implement, and sustain high-quality comprehensive facility and community-based HIV 95-95-95 cascade activities for children, adolescents, and adults in Cameroon under the President's Emergency Plan for AIDS...
This federal Cooperative Agreement award, provided by the U.S. Department of Health and Human Services' Centers for Disease Control and Prevention under the Global AIDS program (CFDA 93.067), will support the Cameroon Baptist Convention Health Board to develop, implement, and sustain high-quality comprehensive HIV cascade activities for children, adolescents, and adults in facility and community-based settings in Cameroon under the President's Emergency Plan for AIDS Relief (PEPFAR). The...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $42,680,510 Cooperative Agreement under the Global AIDS program (CFDA 93.067) to the Shwari Health Association, a non-profit organization in Cameroon. The 5-year award, which commenced on September 30, 2024, will support the SAFECARE-CAMEROON project to develop, implement, and sustain comprehensive facility and community-based HIV services for children, adolescents, and adults in Cameroon. Key objectives include enhancing the...
This Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Global AIDS Program (CFDA 93.067) provides $13,703,623 to the Cameroon Baptist Convention Health Board (CBCHB) from October 2024 through September 2029. The funding supports the development, implementation, and sustainment of high-quality comprehensive facility and community-based HIV 95-95-95 cascade activities for children, adolescents, and adults in Cameroon under the President's Emergency...
This Cooperative Agreement award from the Centers for Disease Control and Prevention's (CDC) Centers for Disease Control and Prevention Investigations and Technical Assistance program (CFDA 93.283) provides $8,536,000.00 to the African Field Epidemiology Network LTD (AFENET) to reinforce immunization systems in the Democratic Republic of Congo, Ethiopia, and Nigeria over a 5-year period from Sep 30, 2024 to Sep 29, 2029. The key products and services to be delivered include strengthening...
This federal Cooperative Agreement award is from the Centers for Disease Control and Prevention (CDC) under the Global AIDS program (CFDA 93.067). The $5,023,124 award to the National Tuberculosis Control Program in Cameroon will support comprehensive efforts to combat HIV/AIDS globally through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). The award funds a range of technical assistance, service delivery, and capacity-building activities aimed at preventing new HIV infections,...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $6,960,000 Cooperative Agreement under the Global AIDS (CFDA 93.067) federal grant program to the Crihss Foundation in Cameroon. The 5-year "Integrated Transformational and Sustainable Sample Transport (INTRASSAT)" project, which began on September 30, 2024, aims to establish an integrated and sustainable sample transport system in Cameroon. The project objectives are to streamline fragmented diagnostic sample referral...
Metabiota, Inc. was awarded a $3.5 million cooperative agreement from the Defense Health Agency under the Department of Defense HIV/AIDS Prevention Program (CFDA 12.350) for the period of October 1, 2021 through September 30, 2023. The award will support Metabiota's efforts to build HIV epidemic control in Cameroon through strengthening HIV prevention, testing, linkage to care and treatment, and viral suppression programs within the Cameroon Defense Force. As part of this cooperative...
This Project Grant award from the Fogarty International Center (CFDA 93.989 - International Research and Research Training) provides $1,000,000.00 to the University of Illinois to study pathogen transmission dynamics between wildlife and human settlements in rural western Uganda. The key objectives are to: 1) conduct longitudinal surveillance of adenovirus in wild non-human primates, domestic animals, insects, and environmental samples; 2) apply advanced phylogenetic and bioinformatics methods...

SURVEILLANCE AND RESPONSE TO AVIAN AND PANDEMIC INFLUENZA: EXPANDING RESPIRATORY SURVEILLANCE PROGRAMS IN CAMEROON - THE PURPOSE OF THIS PROJECT IS TO SUPPORT THE CAMEROON MINISTRY OF HEALTH IN IMPROVING ITS CAPACITY TO CONDUCT ROUTINE INFLUENZA AND OTHER RESPIRATORY DISEASE SURVEILLANCE IN ORDER TO MONITOR, DETECT, RESPOND, AND MITIGATE TRANSMISSION; IMPROVE LABORATORY SYSTEMS FOR VIROLOGIC DETECTION AND MONITORING; AND STRENGTHEN CONNECTIONS BETWEEN NATIONAL INSTITUTIONS IN ORDER TO FULLY PARTICIPATE IN THE GLOBAL INFLUENZA SURVEILLANCE AND RESPONSE SYSTEM (GISRS). IN YEAR 1, METABIOTA IN COLLABORATION WITH THE MINISTRY OF HEALTH AIMS TO ACCOMPLISH THE FOLLOWING COMPONENT 1 OUTCOMES IN INFRASTRUCTURE, EPIDEMIOLOGICAL SURVEILLANCE, LABORATORY SURVEILLANCE, PANDEMIC PREPAREDNESS, AND COMPONENT 2 OUTCOMES IN EPIDEMIOLOGICAL SURVEILLANCE, LABORATORY SURVEILLANCE AND VIRAL RESPIRATORY PATHOGEN SURVEILLANCE. IN COMPONENT 1, WE WILL (A) ASSESS INFLUENZA SURVEILLANCE SYSTEM AND DEVELOP NATIONAL STRATEGIC PLAN FOR INFLUENZA SURVEILLANCE; (B) ESTABLISH/IMPROVE EPIDEMIOLOGIC CAPACITY, ENHANCE EPIDEMIOLOGICAL SURVEILLANCE CAPACITY, AND COORDINATE COMMUNICATION WITH MOA TO IMPLEMENT OR MAINTAIN ANIMAL HUMAN INTERFACE/ONE HEALTH SURVEILLANCE SYSTEM; (C) IMPROVE LABORATORY CAPACITY AND ENHANCE ANIMAL ZOONOTIC INFLUENZA VIRUS KNOWLEDGE TO SUPPORT ANIMAL HUMAN INTERFACE/ONEHEALTH PLATFORM; AND (D) DEVELOP AND MAINTAIN A NATIONAL PANDEMIC INFLUENZA PREPAREDNESS PLAN. IN COMPONENT 2 UNDER EPIDEMIOLOGICAL SURVEILLANCE, WE WILL (A) EVALUATE THE UNUSUAL RESPIRATORY EVENT-BASED SURVEILLANCE (EBS) PIROT PROJECT IMPLEMENTED IN 2017 ? 2018 AND ORGANIZE AN ADVOCACY MEETING TO BUILD COLLABORATION TOWARDS A COORDINATED HUMAN AND ANIMAL SURVEILLANCE SYSTEM; (B) DEVELOP AND REVISE OPERATIONAL GUIDELINES FOR UNUSUAL RESPIRATORY DISEASES (NON-INFLUENZA VIRAL AND BACTERIAL) EBS, UTILIZING A ONE HEALTH APPROACH; (C) BUILD CAPACITY IN FIVE HEALTH FACILITIES TO IMPLEMENT EBS OF UNUSUAL RESPIRATORY DISEASES IN CAMEROON; (D) REVIEW AND DISSEMINATE DATA COLLECTED DURING UNUSUAL RESPIRATORY DISEASE EBS; AND (E) SUPPORT RAPID RESPONSE TEAMS TO INVESTIGATE OUTBREAKS OF UNUSUAL RESPIRATORY EVENTS.

Posted 8/12/21, 12:00 AM